pembrolizumab

Durvalumab and Pabolizumab for lung cancer treatment

Durvalumab and Pabolizumab for lung cancer treatment

Small cell lung cancer (SCLC) is a rapidly developing, invasive lung cancer that accounts for about 15% of all lung cancer cases. Among them, about three-quarters of patients with small […]

TOP10 Best-selling Drugs in 2018

The top spot in the world’s best-selling drug list may not be a suspense in the short term, according to a report by EvaluatePharma, a market research firm. In 2018, […]

Ten Cancer Drugs That “Made Headlines” in 2017

With upgrading of technologies and better understanding of diseases, the death rate caused by cancers is considerably decreased. According to the 2017 Cancer Progress Report released by the American Association […]

Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a leading cause of death among cancer patients. The 5-year overall survival rate in patients with localized cancer is 55.2 %, and this decreases to 4.3 % […]

Immune Checkpoint Inhibitors in Older Adults

Immune Checkpoint Inhibitors in Older Adults

Cancer is primarily a disease of the older adult with more than 50 % of new cases occurring in adults older than 65 years. The care of older adults with cancer can […]

Immune checkpoint inhibitors: a new frontier in bladder cancer

Immune checkpoint inhibitors: a new frontier in bladder cancer

  Immunotherapy and immune checkpoint inhibition in particular present an exciting opportunity for the treatment of bladder cancer. Over the last 30 years, bladder cancer patients have seen few advances in the […]